NCT02403648View on ClinicalTrials.gov

Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

March 31, 2015

Conditions
Hypoglycemia
Interventions
DRUG

BIOD-961

BIOD-961 is a lyophilized glucagon formulation.

DRUG

Lilly Glucagon

DRUG

Novo Glucagon

Sponsors

Lead Sponsor

Biodel
All Listed Sponsors
lead

Biodel

INDUSTRY

NCT02403648 - Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons | Biotech Hunter | Biotech Hunter